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Background:Macitentan is a new endothelin receptor antagonist that is used to treat pulmonary arterial hyper-
tension in humans. Treatment of established pulmonary hypertension with macitentan was studied using the
monocrotaline model of pulmonary hypertension.
Methods: Three groups of rats were created (n = 12): control (CON: macitentan only), monocrotaline (MCT:
monocrotaline only) and macitentan (MACI: macitentan and monocrotaline). Monocrotaline (60 mg/kg) was
injected in the MCT and MACI groups on day 0; volume matched saline was injected in the CON groups.
Macitentan therapy (30 mg/kg/day) was commenced on day 11 in the CON and MACI groups. Serial echocardi-
ography and ECGs were performed. The rats were sacriﬁced if they showed clinical deterioration.
Results: TheMCT andMACI rats showed signs of pulmonary hypertension by day 7 (maximumpulmonary veloc-
ity, CON 1.15 ± 0.15 m/s vs MCT 1.04 ± 0.10 m/s vs MACI 0.99 ± 0.18 m/s; p b 0.05). Both the MCT and MACI
groups developed pulmonary hypertension, but thiswas less severe in theMACI group (day 21 pulmonary artery
acceleration time, MCT 17.55± 1.56 ms vs MACI 22.55 ± 1.00 ms; pulmonary artery deceleration, MCT 34.72±
3.72 m/s2 vs MACI 17.30 ± 1.89 m/s2; p b 0.05). Right ventricular hypertrophy and QT interval increases were
more pronounced in MCT than MACI (right ventricle wall thickness, MCT 0.13 ± 0.1 cm vs MACI 0.10 ±
0.1 cm; QT interval, MCT 85 ± 13 ms vs MACI 71 ± 14 ms; p b 0.05). Survival beneﬁt was not seen in the
MACI group (p = 0.50).
Conclusions: Macitentan treatment improves haemodynamic parameters in established pulmonary hyperten-
sion. Further research is required to see if earlier introduction of macitentan has greater effects.© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Pulmonary arterial hypertension (PAH) is a disease characterised by
raised pulmonary vascular resistance. It has a poor prognosis typically
resulting in progressive right ventricular failure and death. Treatment
in PAH has advanced rapidly over the past decade with the use of
Ca2+ channel blockers, prostanoids, endothelin receptor antagonists
(ERAs) and phosphodiesterase-5 inhibitors [1]. PAH often has an insid-
ious onset, which means that diagnosis and treatment are usually not
begun until the disease is advanced. Recent studies have looked athe support of a British Heart
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land Ltd. This is an open access articlpatients with less severe disease (World Health Organisation (WHO)
class II), and have shown that early initiation of therapy can delay the
progression of the disease [2].
Endothelin is a 21-amino acid peptide which is produced mainly by
the vascular system and acts in a paracrinemanner to regulate vasocon-
striction, cell proliferation, cell migration and ﬁbrosis [3]. Activation of
the endothelin system plays a central role in the pathogenesis of PAH
[3]. ERAs are widely used in clinical practice for patients with WHO
class II to IV symptoms, either as monotherapy or in combination with
other agents [1,4,5]. They have beneﬁcial effects on haemodynamic pa-
rameters, objective measurements of exercise capacity and subjective
symptom scores [1,4,5]. Data regarding ERAs and mortality are limited,
although registry data suggests a survival beneﬁt with the ERA
bosentan [1,4,5]. Macitentan is a new ERAwhich has been shown in an-
imal studies to have improved tissue penetration, longer receptor bind-
ing and afﬁnity for both the endothelin A and B receptors compared
with the older ERA bosentan [6]. The use of macitentan to treat PAH
has been investigated in a phase III clinical trial enrolling WHO class II
to IV patients showing a signiﬁcant improvement in exercise capacitye under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Pulsedwave Doppler recording through the pulmonary artery andmeasurement of
PVmax, PAAT and PAD. The x axismeasures time and the y axismeasures velocity. PAAT is
the time from the beginning of ﬂow to the peak velocity,measured from the x axis. PVmax
is themaximumvelocitymeasured from the y-axis. PAD is the gradient of the initial decel-
eration of the pulmonary velocity proﬁle.
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in morbidity over a followup period of up to 36 months [7].
Monocrotaline is a pyrrolizidine alkaloid, extracted from the plant
Crotalaria spectabilis. A single injection has been shown to generate se-
vere pulmonary hypertension in several species and has been widely
used as an animal model of pulmonary hypertension in the rat [8,9].
The effects of monocrotaline on pulmonary arterial pressures, pulmo-
nary vascular resistance and right ventricular hypertrophy have been
studied using invasive methods with direct pressure methods and
non-invasivemethods including echocardiography (echo) andmagnet-
ic resonance imaging (MRI) [10,11]. These studies have demonstrated a
characteristic change in the pulmonary velocity proﬁle from the typical
rounded shape to a ‘spike and dome’ morphology [10,11]. The echo pa-
rameter ‘pulmonary artery deceleration’ (PAD) is correlated to pulmo-
nary arterial pressure measured invasively and the echo parameter
‘pulmonary artery acceleration time’ (PAAT) is inversely correlated to
both pulmonary pressure and pulmonary vascular resistance measured
invasively [10,11].
Experiments using themonocrotaline model have given positive re-
sults from drug therapy including ERAs, sildenaﬁl, statins and beta
blockers [6,12–15]. The experimental design of these studies has varied
such that some studies have started therapy on the same day as the
monocrotaline injection, i.e. a ‘prevention’ strategy, whereas others
havewaited until there is evidence of the animals displaying pulmonary
hypertension before commencing therapy, i.e. a ‘treatment’ strategy. In
caseswhere ‘prevention’ and ‘treatment’ have been compared there has
been a greater effect with ‘prevention’ than with ‘treatment’ [13,14,16].
These ﬁndings raise questions about the extent to which ‘prevention’
studies are applicable to clinical practice, particularly given that the dra-
matic successes seen in ‘prevention’ studies have not been borne out in
clinical practice.
Animal studies with macitentan administration, given as a ‘preven-
tion’ strategy, have shown a signiﬁcant mortality beneﬁt. In order to
more closely to reﬂect current clinical practice, we have investigated
the safety and efﬁcacy of macitentan administration after the develop-
ment of pulmonary hypertension in the monocrotaline model.
2. Methods
All procedures were carried out in accordance with the UK Animals Scientiﬁc Proce-
dures Act (1986). Invasive pulmonary pressure monitoring in monocrotaline injected
rats has demonstrated that pulmonary pressures are signiﬁcantly raised by day 10 and in-
crease progressively, leading to RV failure and death [11,17]. In the light of such previous
studies we elected to initiate therapy at day 11, in order to mirror the clinical situation
with respect to initiation of treatment. Male Wistar Harlan rats (n = 36; weight 200 g;
Charles River, UK) were arbitrarily assigned to three equal groups (n = 12). All animals
received pulverised chowonly from day 0 to day 11. The control group (CON) received sa-
line injection (3 ml/kg) by intraperitoneal injection on day 0 and macitentan (Actelion
Pharmaceuticals Ltd, Allschwil, Switzerland) 30 mg/kg/day admix to pulverised chow
from day 11 to the day of termination. The monocrotaline only group (MCT) received
monocrotaline 60 mg/kg by intraperitoneal injection on day 0 and pulverised chow only
from day 11 to the day of termination. The macitentan treated group (MACI) received
monocrotaline injection 60 mg/kg by intraperitoneal injection on day 0 and macitentan
30 mg/kg/day admix to pulverised chow day 11 to the day of termination [6]. Monocrota-
line (Sigma-Aldrich Ltd, UK) was dissolved in 1 M hydrochloric acid, then made up to a
concentration of 20 mg/ml with 0.9% saline, the pH corrected to 7.4 using 4 M NaOH.
ECG and echo recordingwas carried out under general anaesthesiawith 2% isoﬂurane.
Electrodes were inserted subcutaneouslywith the negative electrode in the right forepaw,
the positive electrode in the left forepaw and the ground electrode in the right hindpaw.
The electrodes were connected to a Bioamp and Powerlab analogue to digital converter
(AD instruments, New Zealand). Signals were recorded using Labchart (AD Instruments,
New Zealand) and analysed ofﬂine. All intervals were measured from the average of 100
beats using Chart software. ECG was recorded on day 0 immediately prior to injection,
and on day 7, day 14 and day 21. QTc was calculated using Bazett's formula.
Echo images were acquired on an ACUSON Sequoia™ (Acuson Universal Diagnostics
Solution, USA) with a 15 MHz 15L8 transducer. All images were stored on optical media
disks for subsequent ofﬂine analysis. M-mode recordings were taken in the parasternal
short axis view allowing recording of left ventricle (LV) anterior and posterior wall thick-
ness and the internal diameter of the LV in both systole and diastole. Right ventricle (RV)
wall thickness was measured from M-mode recordings in the parasternal long axis view.
Continuous wave Doppler recordings through the pulmonary artery were used to assess
the pulmonary velocity proﬁle. The maximum pulmonary velocity (PVmax), time fromthe onset of pulmonary outﬂow to maximal ﬂow (pulmonary artery acceleration time,
PAAT) and the rate of deceleration of pulmonary ﬂow (pulmonary artery deceleration
time, PAD) were measured (Fig. 1). Echo was recorded on day 0 immediately prior to in-
jection, on day 7, day 14, and day 21.
2.1. Symptomatic endpoints
The animals were weighed and their clinical condition was assessed twice weekly in
the ﬁrst 18 days, and daily thereafter. Animals were sacriﬁced on the day that the follow-
ing pre-speciﬁed endpoints were met, namely evidence of clinical deterioration with re-
duced movement, increased respiratory rate, piloerection and weight loss of N10 g over
2 days. Animals that did not meet these criteria were electively sacriﬁced on day 28. The
animals were sacriﬁced by stunning and cervical dislocation; the heart and lungs were
excised and weighed.
2.2. Statistical methods
The distribution of the data was analysed using the Shapiro–Wilk test. The data were
found to be normally distributed and therefore analysis of the differences between body
weight, heart weight and lung weight was performed using Student's t-test. Comparisons
of the echo and ECGparameters at day 0, day 7, day 14 and day 21weremade using a two-
way repeated measures ANOVA with the two factors being time and treatment group;
time was the repeated measure. Comparisons were made between the three treatment
groups at each timepoint using the Tukey test to correct formultiple comparisons. Survival
analysis was performed using the log-rank (Mantel–Cox) test.3. Results
Table 1 shows that both the MCT group and the MACI group had in-
creased heart weight and decreased body weight compared with the
CON group. The differences between the MCT group and MACI group
were not signiﬁcant. There was no difference in lung weight between
the MACI treated group and the CON group. Although the MCT group
did show an increase in lung weight compared with the CON group,
there was no signiﬁcant difference when the MCT group and MACI
group were compared directly.
Fig. 2 shows that both the MCT and MACI group developed echo ev-
idence of pulmonary hypertension with a change from a ‘rounded’ pul-
monary velocity proﬁle to a ‘spike and dome’ morphology. The timings
of these changes are summarised in Fig. 3. The earliest changes in echo
parameters were seen at day 7 with a reduction in PVmax of 9% in the
MCT group and 13% in the MACI group compared with the CON group
(Fig. 3A). No other parameters were signiﬁcantly altered by day 7. The
reduction of PVmax in both MCT and MACI groups when compared
with the CON group suggests that pulmonary hypertension had begun
to develop by day 7.
Table 1
Body weights on day 21 and heart and lung weights on termination of the CON, MCT and MACI groups.
CON (n = 12) MCT (n = 11–12) MACI (n = 12) p-Value for MCT V MACI
Body weight at day 21 (g) 359 ± 11 331 ± 6⁎ 328 ± 6⁎ 0.70
Heart weight (g) 1.24 ± 0.12 1.541 ± 0.21⁎⁎ 1.46 ± 0.14⁎⁎ 0.28
Lung weight (g) 2.36 ± 1.08 3.206 ± 0.71⁎ 2.85 ± 0.35 0.14
⁎ p b 0.05 MCT or MACI vs CON.
⁎⁎ p b 0.005 MCT or MACI vs CON.
425I.P. Temple et al. / International Journal of Cardiology 177 (2014) 423–428At day 14 therewas evidence of pulmonary hypertension in both the
MCT and MACI groups, with reductions in PVmax of 20% in the MCT
group and 14% in the MACI group compared to the CON group. The
PAAT was reduced by 25% in the MCT group compared with the CON
group and 22% comparedwith theMACI group. Therewas no signiﬁcant
change in PAAT in the MACI group compared with the CON group. No
other signiﬁcant changes were seen between theMACI andMCT groups
(Table 2; Fig. 3).
At day 21, both the MCT and MACI groups continued to show evi-
dence of pulmonary hypertension with a reduction in PAAT of 39% in
the MCT group and 22% in the MACI group compared with the CON
group. The rise in RV pressure caused compression of the LV which re-
sulted in a decrease in LV internal diameter in both diastole and systole
in both the MCT and MACI groups (Table 3). Although the MACI group
continued to show evidence of pulmonary hypertension, this was less
severe than in the MCT group; the MACI group had a 29% greater
PAAT and a 50% lower PAD than the MCT group. Further demonstration
that pulmonary hypertension was less severe in the MACI group than
the MCT group was the ﬁnding that the RV wall thickness in systole
was 23% smaller in the MACI group (Table 3; Fig. 3B–D).
In vivo ECG recordings showed no signiﬁcant changes in any param-
eters at day 7. At day 14, the QT interval was prolonged in the MCT
group by 26% compared with the CON group and by 18% compared
with the MACI group. The QTC interval was prolonged in the MCT
groupby23% comparedwith theCONgroup. There difference inQTC be-
tween the MACI group and both the CON group and MCT group were
not signiﬁcant. At day 21, QT interval was increased by 79% in the
MCT group and by 52% in the MACI group compared with the CON
group. QT interval was shorter by 15% in the MACI group than in the
MCT group. Similarly at day 21, QTC interval was increased by 75% inFig. 2. Echo images showing the development of pulmonary hypertension assessed by the
pulmonary velocity proﬁle. The proﬁle has a typical ‘rounded’ shape prior to injection. At
day 21 no change is seen in the CON animal but the MCT animal shows a change to a typ-
ical ‘spike and dome’morphology with a reduced PAAT and increased PAD. The MACI an-
imal has an intermediate proﬁle between the two groups.the MCT group and by 48% in the MACI group compared with the CON
group. QTC interval was shorter by 15% in the MACI group than in the
MCT group. There were no changes seen in any of the other ECG param-
eters (Table 4).
Freedom from symptomatic endpoints at day 28was 100% in the CON
group, 42% in theMCT group and 58% in theMACI group. Therewas a sig-
niﬁcantly worse survival in both the MCT and MACI groups when com-
pared with the CON group (MCT p = 0.002, MACI p = 0.014). The
difference in freedom from symptomatic endpoints between the MCT
and MACI groups was not statistically signiﬁcant (p = 0.50) (Fig. 4).
4. Discussion
This study shows for the ﬁrst time that treatment with the ERA
macitentan retards and delays the progression of established pulmo-
nary hypertension in the rat monocrotaline model. The pulmonary
pressures in the three groups have been estimated using the echo pa-
rameters PAD and PAAT. As described in the Introduction section both
an increase in PAD and a decrease in PAAT correlate with an increase
in pulmonary artery pressure [10,11]. The earliest signs of pulmonary
hypertension developing are seen by day 7 with a reduction of PVmax
seen in both the MCT and MACI groups. Macitentan treatment was ini-
tiated at day 11, and the data show signiﬁcant slowing of progression of
the echo and ECG parameters of pulmonary hypertension by as early as
day 14 with a greater PAAT in the MACI group than the MCT group
(Fig. 3B). The MACI group showed less severe parameters of pulmonary
hypertension than theMCTgroup at both day 14 and day21 (Fig. 3). De-
spite the early beneﬁcial effects of macitentan on pulmonary pressures
in theMACI group comparedwith theMCT group the evidence suggests
that the pulmonary pressures are increased in the MACI group com-
pared with the CON group by day 21 with a signiﬁcant reduction in
PAAT demonstrated in theMACI group. Delaying the progression of pul-
monary hypertension resulted in reduced structural and electrical re-
modelling with improvements in right ventricular wall thickness and
QT interval at day 21 (Table 4; Fig. 3E) in the MACI group compared
with the MCT group. These ﬁndings suggest that treatment with
macitentan is able to improve haemodynamic parameters in animals
with established pulmonary hypertension in the earlier stages of the
disease. However, the underlying pathogenesis of the monocrotaline
model continues to progress, and pulmonary hypertension continues
to develop despite macitentan treatment (Figs. 3, 4).
In spite of increasing interest in treating patients with PAH earlier in
their disease course, advanced therapies for PAH are considered only in
patients who have proven raised pulmonary vascular resistance and
symptoms [1,2]. In our study, the earliest indication of pulmonary hy-
pertension was seen at day 7 with a reduced PVmax, and there was
clear evidence of pulmonary hypertension in the untreated monocrota-
line group at day 14. This suggests that our experimental protocol is
comparable to the clinical situation.
Previous studies using other compounds to treat pulmonary hyper-
tension in themonocrotalinemodel including statins, endothelin block-
ade, rapamycin and vasoactive intestinal peptide have shown that the
timing of initiation of therapy is crucial [13,14,16,18,19]. In the case of
anti-proliferative therapy such as rapamycin early therapy has been
shown to prevent the development of pulmonary hypertension, but to
be ineffective if given after pulmonary hypertension has developed
Fig. 3.Development of pulmonary hypertension.Mean and SEM plotted at each time point. TheMACI groupwas comparedwith theMCT group and the CON group by a t-test. Pulmonary
hypertension developed in theMACI group by day 7 (i.e. before the initiation ofmacitentan)with a reduced PVmax. There is a signiﬁcant improvement in theMACI group compared to the
MCT group at day 14 and day 21 with a reduced PAD, right ventricular wall thickness in systole and QT interval and an increased pulmonary artery acceleration time.
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has a dramatic effect with a survival beneﬁt, although it has been sug-
gested that early therapy may delay rather than stop the development
of pulmonary hypertension [16,18,19]. This can be compared with initi-
ation of bosentan after pulmonary hypertension has developed, which
has demonstrated more modest improvements in haemodynamic pa-
rameters and equivocal survival beneﬁt [18].
The increase in heart weight seen in both theMCT andMACI groups
is consistent with previous studies in the monocrotaline model that
have demonstrated RV hypertrophy and an increased RV weight [12,
16]. Similarly the increase in lung weight seen in the MCT group hasTable 2
Echo measurements on day 14 for CON, MCT and MACI groups.
CON (n = 11/12) MC
PAAT ms 30.2 ± 1.0 22.
PAD m/s2 14.9 ± 1.4 18.
PVmax m/s 1.20 ± 0.04 0.9
RV internal diameter (diastole) (cm) 0.16 ± 0.03 0.1
RV internal diameter (systole) (cm) 0.07 ± 0.01 0.0
RV wall thickness (diastole) (cm) 0.05 ± 0.00 0.0
RV wall thickness (systole) (cm) 0.07 ± 0.01 0.0
LV internal diameter (diastole) (cm) 0.75 ± 0.01 0.7
LV internal diameter (systole) (cm) 0.34 ± 0.01 0.3
LV anterior wall thickness (diastole) (cm) 0.17 ± 0.00 0.1
LV anterior wall thickness (systole) (cm) 0.29 ± 0.01 0.3
Table showing echo parameters of pulmonary hypertension at day 14.
⁎ p b 0.05 MCT or MACI vs CON.
⁎⁎ p b 0.005 MCT or MACI vs CON.
† p b 0.05 MCT vs MACI.
†† p b 0.05 MCT vs MACI.previously been demonstrated in the lungs in association with an in-
ﬂammatory inﬁltrate [16]. There was no statistically signiﬁcant differ-
ence in the lung weight in the MACI group compared with the CON
group suggesting a relative decrease in inﬂammation within the lungs
of the MACI group compared with the MCT group, but direct compari-
son did not show a difference between the MCT and MACI groups. The
reduction in body weight in both the MCT and MACI groups compared
with the CON group is again in keeping with previous studies and was
used as a marker of clinical deterioration in the animal [12].
The mechanism by which monocrotaline treatment leads to pulmo-
nary hypertension is still debated [3]. The initial insult is thought toT (n = 11/12) MACI (n = 11/12) p-Value for MCT V MACI
8 ± 1.7⁎⁎ 29.1 ± 0.9†† 0.00
8 ± 1.5 16.3 ± 1.2† 0.55
6 ± 0.02⁎⁎ 1.03 ± 0.03⁎⁎ 0.39
7 ± 0.02 0.22 ± 0.02 0.34
8 ± 0.02 0.10 ± 0.01 0.82
6 ± 0.01 0.06 ± 0.00 0.96
9 ± 0.01 0.08 ± 0.00 0.90
0 ± 0.02 0.70 ± 0.01⁎ 0.99
2 ± 0.02 0.30 ± 0.02 0.87
8 ± 0.01 0.18 ± 0.01 0.99
1 ± 0.01 0.34 ± 0.02 0.99
Table 3
Echo measurements for day 21 of CON, MCT and MACI groups.
CON (n = 11/12) MCT (n = 11) MACI (n = 11/12) p-Value for MCT V MACI
PAAT ms 28.7 ± 0.9 17.5 ± 1.6⁎⁎ 22.5 ± 1.0⁎⁎,† 0.02
PAD m/s2 15.8 ± 2.2 34.7 ± 3.7⁎⁎ 17.3 ± 1.9†† 0.00
PVmax m/s 1.18 ± 0.04 0.97 ± 0.03⁎⁎ 1.00 ± 0.05⁎⁎ 0.80
RV internal diameter (diastole) (cm) 0.16 ± 0.02 0.27 ± 0.03⁎⁎ 0.21 ± 0.02 0.13
RV internal diameter (systole) (cm) 0.08 ± 0.02 0.14 ± 0.04⁎ 0.12 ± 0.03 0.66
RV wall thickness (diastole) (cm) 0.05 ± 0.00 0.09 ± 0.01⁎⁎ 0.07 ± 0.01 0.12
RV wall thickness (systole) (cm) 0.07 ± 0.01 0.13 ± 0.01⁎⁎ 0.10 ± 0.01⁎,† 0.02
LV internal diameter (diastole) (cm) 0.78 ± 0.01 0.66 ± 0.04⁎⁎ 0.68 ± 0.02⁎⁎ 0.64
LV internal diameter (systole) (cm) 0.39 ± 0.02 0.26 ± 0.03⁎⁎ 0.27 ± 0.02⁎⁎ 0.96
LV anterior wall thickness (diastole) (cm) 0.17 ± 0.01 0.21 ± 0.02 0.21 ± 0.01 0.94
LV anterior wall thickness (systole) (cm) 0.29 ± 0.01 0.37 ± 0.03⁎⁎ 0.34 ± 0.02 0.18
Table showing echo parameters of pulmonary hypertension at day 21.
⁎ p b 0.05 MCT or MACI vs CON.
⁎⁎ p b 0.005 MCT or MACI vs CON.
† p b 0.05 MCT vs MACI.
†† p b 0.05 MCT vs MACI.
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sponse [9]. Progressive smooth muscle medial hypertrophy takes place
from day ~4, and increases progressively until day 15 [9,20]. Circulating
levels of endothelin are raised in the monocrotaline model and these
raised levels are not affected by ERAs, even if these drugs are given at
the same time as themonocrotaline injection [19]. The beneﬁcial effects
of ERAs are thought to be attributable to a combination of improved en-
dothelial function, vasodilating properties and a reduction of smooth
muscle hypertrophy within the media of the pulmonary vessels [3,18,
19,21,22]. Given the importance of inﬂammation and medial hypertro-
phy in the early stages of themonocrotalinemodel it is tempting to sug-
gest that macitentan treatment may limit the pro-inﬂammatory and
proliferative effects of endothelin if it is given early in the model devel-
opment, before pulmonary hypertension has developed. The relatively
rapid improvement in haemodynamic parameters seen in our study
suggests that the vasodilating effects of endothelin blockade may be
more relevant in established pulmonary hypertension as was present
in our study.
QTC prolongation has been demonstrated in both human and animal
studies of pulmonary hypertension [23–26]. In patients with PAH the
QTC is raised and a QTC of greater than 480ms is an independent predic-
tor of mortality [25]. In addition to this the QTC is correlated to pulmo-
nary pressures and right ventricular dilation and inversely correlated
to right ventricular function [25]. Animal studies have shown that the
prolongation of QT interval is due to a reduction in repolarizing K+ cur-
rents and a prolongation of the ventricular action potential and that this
can provide a substrate for ventricular arrhythmias [23,24,26]. The rela-
tive improvement in QT and QTC interval in the MACI group suggests
that macitentanmay act to reduce the risk of arrhythmias aswell as im-
proving haemodynamic parameters.
The CON group receivedmacitentan treatment in order to assess the
safety proﬁle of macitentan. There were no adverse events seen in the
CON group conﬁrming the safety of macitentan. The echo and ECG ﬁnd-
ings in the CON group were comparable to previous studies and ourTable 4
ECG measurements on day 21 or CON, MCT and MACI groups.
CON (n = 12) MCT (n = 11)
Heart rate (bpm) 393.50 ± 7.77 372.10 ± 8.10
PR interval (ms) 48.54 ± 3.29 48.21 ± 4.705
QRS duration (ms) 15.29 ± 2.58 14.07 ± 1.40
QT interval (ms) 47.00 ± 3.99 84.56 ± 12.55⁎
QTC interval (ms) 120 ± 3.14 210.3 ± 9.34⁎⁎
Table showing ECG measurements at day 14.
⁎⁎ p b 0.005 MCT or MACI vs CON.
† p b 0.05 MCT vs MACI.
†† p b MCT vs MACI.own unpublished data in which control groups received saline injec-
tions and no treatment, and would be consistent with the notion that
macitentan treatment has no major effects on animals without pulmo-
nary hypertension [27].
The results from our study are in keeping with clinical trials of PAH,
in which despite early functional improvements, clear mortality beneﬁt
has not been shown [1]. In clinical practice PAH has an insidious presen-
tation and diagnosis is typically late. Therefore the relevance of animal
studies in which treatment is commenced before the development of
pulmonary hypertension to clinical practice is debatable. The results of
our study suggest that treatment with macitentan may offer beneﬁts
in terms of haemodynamic parameters, right ventricular function and
QT prolongation. The relative contribution of anti-inﬂammatory, anti-
proliferative and vasodilating actions of ERAs to treatment of PAH at dif-
ferent timepoints in the disease process are yet to be determined.
4.1. Study limitations
The safety of macitentan was demonstrated by the lack of adverse
events in the CON group. A more robust analysis of the effects of
macitentan on animals without pulmonary hypertensionwould require
the addition of a control group that received a saline injection and no
macitentan. However, themain aimof the studywas to compare thedif-
ferences between the untreated pulmonary hypertension in the MCT
group and the treated pulmonary hypertension in the MACI group.
This study demonstrates that macitentan treatment delays the progres-
sion of MCT induced pulmonary hypertension compared to the untreat-
ed animals. Similar beneﬁts have also been shown with other therapies
including the ERA bosentan and the phosphodiesterase-5 inhibitor sil-
denaﬁl [12,13,16,18].
We elected to use echocardiography to monitor the progression of
pulmonary hypertension on the basis that it allows serial non-invasive
measures, which have previously been validated against invasive
pressure measurements in the right ventricle. Direct measurement ofMACI (n = 12) p-Value for MCT V MACI
380.50 ± 12.15 0.79
47.87 ± 4.68† 0.92
14.33 ± 1.17 0.52
⁎ 70.69 ± 13.95⁎⁎,†† 0.00
178.1 ± 10.81⁎⁎,†† 0.00
Fig. 4. Kaplan–Meir curves showing the freedom from symptomatic endpoints. The ani-
mals were sacriﬁced on the day they met their symptomatic endpoints. There is a signiﬁ-
cant difference between the CON and MACI treated groups (p = 0.01) but no difference
between the MACI treated and MCT groups (p = 0.50).
428 I.P. Temple et al. / International Journal of Cardiology 177 (2014) 423–428right-sided pressures and pulmonary vascular resistance may allow
greater sensitivity to detect the effects of macitentan treatment, but
are impractical for serial measurements.
Macitentan was administered via food admix to animal cages hous-
ing four rats. The dose was adjusted to animal weight and food intake
was monitored to ensure that the correct dose of macitentan was
being consumed on average between the four rats. However, it was
not possible to ensure that each individual rat received exactly the spec-
iﬁed dose. When the animals deteriorated their food intake may have
diminished. However, the earliest deterioration in the MACI group
was seen on day 21, meaning that the animal would have received
macitentan treatment for a minimum of 10 days.
It is interesting to note that despite the use of the same dose regime of
monocrotaline to that of Iglarz et al. we have seen a considerably more
severe phenotype in the MCT group than previously demonstrated. In
our study, 28-day freedom from symptomatic endpoints was 42% com-
pared with a survival at day 28 of approximately 90% in their experi-
ments [6]. Although these outcomes are not directly comparable the
severe phenotype seen in our experimentsmay be attributable to the rel-
atively lowbodyweight of the rats at the timeofmonocrotaline injection.
Therefore the beneﬁts of macitentan therapy may to some extent have
been masked by the severity of the MCT model phenotype, due to more
rapid progression of the underlying lung pathology together with a
shorter treatment duration before symptomatic endpointswere reached.
In conclusion, this study shows that treatmentwithmacitentan pro-
vides worthwhile haemodynamic beneﬁts in established pulmonary
hypertension in association with reduced progression of the disease
process. Taken together with others' data our results reinforce the no-
tion that greater beneﬁt may occur when treatment is initiated earlier
in the course of the disease.
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